Skip to main content
. 2019 Jun 7;58(18):2657–2662. doi: 10.2169/internalmedicine.2604-18

Figure 2.

Figure 2.

The levels of hepatitis C virus RNA over time in Case 1 treated with direct-acting antiviral agents. The patient was treated for 24 weeks with daclatasvir/asunaprevir, for 12 weeks with glecaprevir/pibrentasvir, and for 12 weeks with daclatasvir/asunaprevir/beclabuvir. Non-responsiveness was the outcome of all treatments.